A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer

Journal of Immunology

Volumn 186, Issue 2, 2011, Pages 685-696

  Chinnasamy, Nachimuthu ^a   Wargo, Jennifer A ^a   Yu, Zhiya ^a   Rao, Mahadev ^a   Frankel, Timothy L ^a   Riley, John P ^a   Hong, Jenny J ^a   Parkhurst, Maria R ^a   Feldman, Steven A ^a   Schrump, David S ^a   Restifo, Nicholas P ^a   Robbins, Paul F ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; CDR3 ALPHA CHAIN; EPITOPE; HEPATITIS B CORE ANTIGEN; HLA A 0201 ANTIGEN; HLA A ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 12; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 6; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; THREONINE; UNCLASSIFIED DRUG;

ALPHA CHAIN; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER GENE THERAPY; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL CLONE; CONTROLLED STUDY; CYTOKINE RELEASE; ESOPHAGUS CANCER; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET CELL; TRANSGENIC MOUSE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MELANOMA; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

EID: 79251588743     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001775     Document Type: Article

References (62)

1. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
2. Rosenberg, S. A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287.
3. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
4. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.
5. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
6. Dudley, M. E., J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg. 2003. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26: 332-342.
7. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
8. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
9. Suri, A. 2006. Cancer testis antigens - their importance in immunotherapy and in the early detection of cancer. Expert Opin. Biol. Ther. 6: 379-389.
10. Simpson, A. J., O. L. Caballero, A. Jungbluth, Y. T. Chen, and L. J. Old. 2005. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5: 615-625.
11. Caballero, O. L., and Y. T. Chen. 2009. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100: 2014-2021.
12. Zhao, Y., Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan. 2005. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174: 4415-4423.
13. Wargo, J. A., P. F. Robbins, Y. Li, Y. Zhao, M. El-Gamil, D. Caragacianu, Z. Zheng, J. A. Hong, S. Downey, D. S. Schrump, et al. 2009. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol. Immunother. 58: 383-394.
14. Robbins, P. F., Y. F. Li, M. El-Gamil, Y. Zhao, J. A. Wargo, Z. Zheng, H. Xu, R. A. Morgan, S. A. Feldman, L. A. Johnson, et al. 2008. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180: 6116-6131.
15. Barker, P. A., and A. Salehi. 2002. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J. Neurosci. Res. 67: 705-712.
16. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
17. Yang, B., S. M. O'Herrin, J. Wu, S. Reagan-Shaw, Y. Ma, K. M. Bhat, C. Gravekamp, V. Setaluri, N. Peters, F. M. Hoffmann, et al. 2007. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 67: 9954-9962.
18. Monte, M., M. Simonatto, L. Y. Peche, D. R. Bublik, S. Gobessi, M. A. Pierotti, M. Rodolfo, and C. Schneider. 2006. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 103: 11160-11165.
19. Liu, W., S. Cheng, S. L. Asa, and S. Ezzat. 2008. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 68: 8104-8112.
20. Chomez, P., O. De Backer, M. Bertrand, E. De Plaen, T. Boon, and S. Lucas. 2001. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61: 5544-5551. (Pubitemid 32694940)
21. De Smet, C., C. Lurquin, B. Lethé, V. Martelange, and T. Boon. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19: 7327-7335.
22. Roeder, C., B. Schuler-Thurner, S. Berchtold, G. Vieth, P. Driesch, G. Schuler, and M. Lüftl. 2005. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch. Dermatol. Res. 296: 314-319.
23. Tajima, K., Y. Obata, H. Tamaki, M. Yoshida, Y. T. Chen, M. J. Scanlan, L. J. Old, H. Kuwano, T. Takahashi, T. Takahashi, and T. Mitsudomi. 2003. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 42: 23-33.
24. Filho, P. A., A. López-Albaitero, L. Xi, W. Gooding, T. Godfrey, and R. L. Ferris. 2009. Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. Int. J. Cancer 125: 1912-1920.
25. Luo, G., S. Huang, X. Xie, E. Stockert, Y. T. Chen, B. Kubuschok, and M. Pfreundschuh. 2002. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun. 2: 11.
26. Jungbluth, A. A., S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y. T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, and H. J. Cho. 2005. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106: 167-174.
27. Bolli, M., T. Kocher, M. Adamina, U. Guller, P. Dalquen, P. Haas, M. Mirlacher, F. Gambazzi, F. Harder, M. Heberer, et al. 2002. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann. Surg. 236: 785-793, discussion 793.
28. Gure, A. O., R. Chua, B. Williamson, M. Gonen, C. A. Ferrera, S. Gnjatic, G. Ritter, A. J. Simpson, Y. T. Chen, L. J. Old, and N. K. Altorki. 2005. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 11: 8055-8062.
29. Dhodapkar, M. V., K. Osman, J. Teruya-Feldstein, D. Filippa, C. V. Hedvat, K. Iversen, D. Kolb, M. D. Geller, H. Hassoun, T. Kewalramani, et al. 2003. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 3: 9.
30. Valmori, D., D. Liénard, G. Waanders, D. Rimoldi, J. C. Cerottini, and P. Romero. 1997. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res. 57: 735-741.
31. Chaux, P., V. Vantomme, V. Stroobant, K. Thielemans, J. Corthals, R. Luiten, A. M. Eggermont, T. Boon, and P. van der Bruggen. 1999. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med. 189: 767-778.
32. Manici, S., T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, and M. P. Protti. 1999. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189: 871-876.
33. Schultz, E. S., B. Lethé, C. L. Cambiaso, J. Van Snick, P. Chaux, J. Corthals, C. Heirman, K. Thielemans, T. Boon, and P. van der Bruggen. 2000. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 60: 6272-6275.
34. Kobayashi, H., Y. Song, D. S. Hoon, E. Appella, and E. Celis. 2001. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 61: 4773-4778.
35. Kawashima, I., S. J. Hudson, V. Tsai, S. Southwood, K. Takesako, E. Appella, A. Sette, and E. Celis. 1998. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59: 1-14.
36. Graff-Dubois, S., O. Faure, D. A. Gross, P. Alves, A. Scardino, S. Chouaib, F. A. Lemonnier, and K. Kosmatopoulos. 2002. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. 169: 575-580. (Pubitemid 34686181)
37. Parkhurst, M. R., J. Joo, J. P. Riley, Z. Yu, Y. Li, P. F. Robbins, and S. A. Rosenberg. 2009. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 15: 169-180.
38. Riker, A. I., U. S. Kammula, M. C. Panelli, E. Wang, G. A. Ohnmacht, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 2000. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int. J. Cancer 86: 818-826.
39. Zhao, Y., Z. Zheng, C. J. Cohen, L. Gattinoni, D. C. Palmer, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2006. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13: 151-159.
40. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16: 457-472.
41. Morgan, R. A., M. E. Dudley, Y. Y. Yu, Z. Zheng, P. F. Robbins, M. R. Theoret, J. R. Wunderlich, M. S. Hughes, N. P. Restifo, and S. A. Rosenberg. 2003. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171: 3287-3295.
42. van der Bruggen, P., J. Bastin, T. Gajewski, P. G. Coulie, P. Boël, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24: 3038-3043.
43. Yang, S., C. J. Cohen, P. D. Peng, Y. Zhao, L. Cassard, Z. Yu, Z. Zheng, S. Jones, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2008. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 15: 1411-1423.
44. Zhao, Y., A. D. Bennett, Z. Zheng, Q. J. Wang, P. F. Robbins, L. Y. Yu, Y. Li, P. E. Molloy, S. M. Dunn, B. K. Jakobsen, et al. 2007. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179: 5845-5854.
45. Miconnet, I., C. Servis, J. C. Cerottini, P. Romero, and F. Lévy. 2000. Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A* 0201-restricted peptide tumor antigen MAGE-3271-279. J. Biol. Chem. 275: 26892-26897.
46. Valmori, D., U. Gileadi, C. Servis, P. R. Dunbar, J. C. Cerottini, P. Romero, V. Cerundolo, and F. Lévy. 1999. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189: 895-906.
47. Parkhurst, M. R., J. P. Riley, T. Igarashi, Y. Li, P. F. Robbins, and S. A. Rosenberg. 2004. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin. Cancer Res. 10: 4688-4698.
48. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152: 163-175.
49. Bredenbeck, A., V. M. Hollstein, U. Trefzer, W. Sterry, P. Walden, and F. O. Losch. 2008. Coordinated expression of clustered cancer/testis genes encoded in a large inverted repeat DNA structure. Gene 415: 68-73.
50. Zeh, H. J., III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994.
51. Weiser, T. S., G. A. Ohnmacht, Z. S. Guo, M. R. Fischette, G. A. Chen, J. A. Hong, D. M. Nguyen, and D. S. Schrump. 2001. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann. Thorac. Surg. 71: 295-301, discussion 301-302.
52. Schuler-Thurner, B., E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195: 1279-1288.
53. Sadanaga, N., H. Nagashima, K. Mashino, K. Tahara, H. Yamaguchi, M. Ohta, T. Fujie, F. Tanaka, H. Inoue, K. Takesako, et al. 2001. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7: 2277-2284.
54. Mackensen, A., B. Herbst, J. L. Chen, G. Köhler, C. Noppen, W. Herr, G. C. Spagnoli, V. Cerundolo, and A. Lindemann. 2000. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer 86: 385-392.
55. Gajewski, T. F., F. Fallarino, A. Ashikari, and M. Sherman. 2001. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7(3, Suppl.): 895s-901s.
56. Carrasco, J., A. Van Pel, B. Neyns, B. Lethé, F. Brasseur, N. Renkvist, P. van der Bruggen, N. van Baren, R. Paulus, K. Thielemans, et al. 2008. Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J. Immunol. 180: 3585-3593.
57. Banchereau, J., A. K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K. M. Wittkowski, N. Bhardwaj, et al. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61: 6451-6458.
58. Tyagi, P., and B. Mirakhur. 2009. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin. Lung Cancer 10: 371-374.
59. Brichard, V. G., and D. Lejeune. 2007. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25(Suppl. 2): B61-B71.
60. Marchand, M., C. J. Punt, S. Aamdal, B. Escudier, W. H. Kruit, U. Keilholz, L. Håkansson, N. van Baren, Y. Humblet, P. Mulders, et al. 2003. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39: 70-77.
61. Atanackovic, D., N. K. Altorki, Y. Cao, E. Ritter, C. A. Ferrara, G. Ritter, E. W. Hoffman, C. Bokemeyer, L. J. Old, and S. Gnjatic. 2008. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl. Acad. Sci. USA 105: 1650-1655.
62. Overwijk, W. W., M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. Dellemijn, P. A. Antony, P. J. Spiess, D. C. Palmer, et al. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198: 569-580.